Small Stocks, Big Money™

RanMarine Technology has unveiled its new MegaShark, a mid-sized autonomous surface vessel (ASV) designed to revolutionize waterway clean-up efforts. The electric-powered MegaShark, offering over five times the capacity of its predecessor, is engineered to efficiently remove floating waste, algae, and biomass from various aquatic environments. With versatile operation modes and advanced autonomous navigation, the MegaShark addresses a global $20 billion market opportunity. As RanMarine prepares for a near-term IPO, this launch underscores its commitment to delivering sustainable, cutting-edge solutions that enhance waterway health and environmental impact.

GreenPower Motor (Nasdaq: GP) is set to deliver five of its Type D BEAST all-electric, zero-emission school buses to two California school districts this week. Four buses will be delivered to Cutler-Orosi Joint Unified School District and one to Terra Bella Union Elementary School District. GreenPower's purpose-built BEAST models, known for their safety and sustainability, are a top choice for districts aiming to leverage state incentives. With additional deliveries planned in California and Oregon, GreenPower continues to lead in the transition to clean school transportation.

Zomedica Corp. (NYSE American: ZOM) posted solid Q2 2024 financials with $6.1 million in revenue, a 2% year-over-year increase driven by a 68% growth in diagnostics segment sales, notably for its TRUFORMA® and VETGuardian® products. The company achieved a strong 71% gross margin, up from 67% last year, reflecting efficiency gains. Zomedica ended the quarter with $83 million in liquidity, positioning it well to support ongoing growth initiatives, including international expansion and new product launches. Despite a net loss due to non-cash impairment charges, Zomedica's recurring revenue base remains robust, with consumables making up 72% of sales.

bioAffinity Technologies (Nasdaq: BIAF) generated $2.4 million in Q2 2024 revenue, driven by a 217% quarter-over-quarter increase in CyPath® Lung test sales. The company's lung cancer diagnostic test is gaining traction, now reaching physicians in eight states beyond its initial Texas market. This surge prompted an 85% upward revision in the full-year CyPath® Lung sales forecast. As bioAffinity continues to expand its reach and bolster its operations, the company remains well-positioned to capture a significant share of the U.S. lung cancer diagnostics market, projected to hit $4.7 billion by 2030.